These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 29307245)

  • 1. Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech Republic.
    Adenubiova E; Arenberger P; Gkalpakioti P; Arenbergerova M; Jircikova J; Dolezal T; Gkalpakiotis S
    J Dermatolog Treat; 2018 Sep; 29(6):579-582. PubMed ID: 29307245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.
    Papp KA; Yang M; Sundaram M; Jarvis J; Betts KA; Bao Y; Signorovitch JE
    Value Health; 2018 Jan; 21(1):1-8. PubMed ID: 29304933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab for psoriasis in Greece: clinical experience in a tertiary referral centre.
    Fotiadou C; Lazaridou E; Sotiriou E; Ioannides D
    J Eur Acad Dermatol Venereol; 2012 Oct; 26(10):1298-303. PubMed ID: 21967627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.
    Papp K; Thaçi D; Marcoux D; Weibel L; Philipp S; Ghislain PD; Landells I; Hoeger P; Kotkin C; Unnebrink K; Seyger M; Williams D
    Lancet; 2017 Jul; 390(10089):40-49. PubMed ID: 28478975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behavior in real life clinical practice.
    Esposito M; Prignano F; Rongioletti F; Hansel K; Bianchi L; Pescitelli L; Lazzeri L; Ricceri F; Mugheddu C; Bavetta M; Zangrilli A; Bianchi L; Bini V; Stingeni L
    J Dermatolog Treat; 2019 Aug; 30(5):441-445. PubMed ID: 30273075
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative effectiveness of adalimumab versus ustekinumab in the treatment of severe chronic plaque psoriasis: The results based on data from the program "treatment of moderate and severe forms of plaque psoriasis (B.47)" of the National Health Fund in Poland.
    Owczarek W; Nowakowska A; Walecka I; Ciechanowicz P; Reich A; Lesiak A; Borkowska E; Śliwczyński A; Narbutt J
    Dermatol Ther; 2022 Jun; 35(6):e15481. PubMed ID: 35363386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab Efficacy in Patients with Psoriasis Who Received or Did Not Respond to Prior Systemic Therapy: A Pooled Post Hoc Analysis of Results from Three Double-Blind, Placebo-Controlled Clinical Trials.
    Papp KA; Armstrong AW; Reich K; Karunaratne M; Valdecantos W
    Am J Clin Dermatol; 2016 Feb; 17(1):79-86. PubMed ID: 26547918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab: A Review in Chronic Plaque Psoriasis.
    Burness CB; McKeage K
    Drugs; 2015 Dec; 75(18):2119-30. PubMed ID: 26586242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of adalimumab in the treatment of moderate-to-severe psoriasis: A retrospective study of 100 patients in daily practice.
    Armesto S; Coto-Segura P; Mayorga J; Illaro A; Santos-Juanes J
    J Dermatolog Treat; 2015 Feb; 26(1):49-53. PubMed ID: 24552591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis.
    Carrera CG; Dapavo P; Malagoli P; Naldi L; Arancio L; Gaiani F; Egan CG; Di Mercurio M; Cattaneo A
    J Dermatolog Treat; 2018 Aug; 29(5):481-486. PubMed ID: 29058948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
    Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
    Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful adalimumab treatment of a psoriasis vulgaris patient with hemodialysis for renal failure: A case report and a review of the previous reports on biologic treatments for psoriasis patients with hemodialysis for renal failure.
    Kusakari Y; Yamasaki K; Takahashi T; Tsuchiyama K; Shimada-Omori R; Nasu-Tamabuchi M; Aiba S
    J Dermatol; 2015 Jul; 42(7):727-30. PubMed ID: 25916786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis.
    Menter A; Thaçi D; Papp KA; Wu JJ; Bereswill M; Teixeira HD; Rubant S; Williams DA
    J Am Acad Dermatol; 2015 Sep; 73(3):410-9.e6. PubMed ID: 26190240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
    J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of anti-IL-23 and anti-IL-17 after adalimumab failure in psoriatic patients.
    Mastorino L; Susca S; Cariti C; Sliquini N; Verrone A; Stroppiana E; Ortoncelli M; Dapavo P; Ribero S; Quaglino P
    J Eur Acad Dermatol Venereol; 2023 Sep; 37(9):1848-1853. PubMed ID: 37113043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term treatment of psoriatic patients with adalimumab reduces disease severity and maintains a favorable lipid pattern and a low Atherogenic Index.
    Zangrilli A; Bavetta M; Scaramella M; Bianchi L
    G Ital Dermatol Venereol; 2018 Apr; 153(2):146-154. PubMed ID: 29564871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of adalimumab in psoriatic patients previously treated with etanercept in a real-world setting.
    Fonseca E; Iglesias R; Paradela S; Fernández-Torres RM; Elberdín L
    J Dermatolog Treat; 2015 Jun; 26(3):217-22. PubMed ID: 24920071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption.
    Gordon KB; Gottlieb AB; Langely RG; van de Kerkhof P; Belasco KT; Sundaram M; Okun M; Serra L
    J Eur Acad Dermatol Venereol; 2015 Apr; 29(4):767-76. PubMed ID: 25284275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
    Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
    Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of adalimumab in the treatment of scalp and nail affection in patients with moderate to severe plaque psoriasis in routine clinical practice.
    Khobzey K; Liskova I; Szegedi A; Pavlovsky L; Lunder T; Kingo K; Miljković J; Péč J; Bohinc M; Hojnik M
    Acta Dermatovenerol Alp Pannonica Adriat; 2017 Mar; 26(1):11-14. PubMed ID: 28352929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.